Skip to content
AnalystLens

Incyte 8-K Report, Financial Results (Jul 29, 2025)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed July 29, 2025
Period End
July 29, 2025
Security
INCY
In the record · 2016–202610-K1510-Q348-K107

INCY filed 15 annual reports (10-K), 34 quarterly reports (10-Q) and 107 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Oct ’17Oct ’17
  2. Leadership change8-K · May ’20May ’20
  3. Leadership change8-K · Apr ’22Apr ’22
  4. Material agreement8-K · Jul ’24Jul ’24

01—Abstract

Summary

Summary of the 8-K filed July 29, 2025. Cited figures are marked; the original filing is the authoritative source.

Incyte Corporation reported second-quarter 2025 results on July 29, 2025, per a press release furnished as Exhibit 99.1.

Total GAAP revenues were $1,215,529 thousanda ($1.22 billion) for Q2 2025, compared with $1,043,759 thousand in Q2 2024, and GAAP net income was $404,999 thousand, or $2.04 per diluted share, versus a net loss of $444,601 thousand in the prior-year quarter. The quarter was helped by a $242.3 million benefit from a contract dispute settlement with Novartis, which reduced the Jakafi royalty rate by 50% beginning January 1, 2025 and resulted in a $280.0 million payment for royalties through December 31, 2024. Prior-year results included $691.9 million of R&D expense tied to the Escient acquisition, so year-over-year comparisons are distorted.

Product revenue drivers were strong. Jakafi net product revenues were $764 millionb (+8% Y/Y), Opzelura was $164 million (+35% Y/Y), and Niktimvo, launched in the first quarter of 2025, generated $36 million. Incyte raised its full-year 2025 Jakafi revenue guidance to $3,000–$3,050 million and its other oncology product guidance to $500–$520 million.

Cash, cash equivalents and marketable securities were $2.4 billionc at June 30, 2025, and Bill Meury became President and CEO effective June 26, 2025. The filing highlights several regulatory and clinical catalysts for the second half of 2025, including Phase 3 tafasitamab data in first-line DLBCL, Phase 1 proof-of-concept data for INCA033989 in myelofibrosis, and a September 19, 2025 PDUFA date for the pediatric Opzelura sNDA after a three-month extension. Zynyz and Monjuvi received FDA approvals in May and June 2025.

02—Key points

Key Highlights

  1. Total GAAP revenues of $1,215,529 thousand in Q2 2025, up from $1,043,759 thousand in Q2 2024 (+16% Y/Y as reported).
  2. GAAP diluted EPS of $2.04 in Q2 2025 versus a loss of $2.04 per share in Q2 2024; Non-GAAP diluted EPS was $1.57.
  3. A $242.3 million contract dispute settlement benefit with Novartis reduced the Jakafi royalty rate by 50% from January 1, 2025, and Incyte paid $280.0 million for prior disputed royalties.
  4. Jakafi net product revenues of $764 million (+8% Y/Y) and Opzelura net product revenues of $164 million (+35% Y/Y).
  5. Full-year 2025 guidance raised: Jakafi to $3,000–$3,050 million and other oncology products to $500–$520 million; GAAP R&D guidance raised to $1,965–$1,995 million.
  6. Cash, cash equivalents and marketable securities of $2.4 billion at June 30, 2025, versus $2.2 billion at December 31, 2024.
  7. Bill Meury became President and CEO effective June 26, 2025, succeeding Hervé Hoppenot.

03—Questions

Frequently Asked Questions

  1. Why did GAAP net income swing to a profit this quarter?

    Q2 2025 GAAP net income of $404,999 thousand compares with a net loss of $444,601 thousand in Q2 2024. The prior-year quarter included $691.9 million of R&D expense from the Escient acquisition, and the current quarter benefited from a $242.3 million contract dispute settlement gain tied to the Novartis royalty agreement, alongside growth in net product revenues.

  2. What did the Novartis settlement change?

    Under the May 2025 settlement, the royalty rate Incyte pays Novartis on future U.S. Jakafi net sales was reduced by 50% beginning January 1, 2025. Incyte paid $280.0 million to settle disputed royalties through December 31, 2024. The reduced royalty for the quarter ending March 31, 2025 was approximately $14.9 million.

  3. What are the key catalysts for the second half of 2025?

    The filing cites Phase 3 data for tafasitamab in first-line DLBCL, Phase 1 data for INCA033989 in myelofibrosis as monotherapy and with ruxolitinib, initial proof-of-concept data for KRASG12D and TGFßR2×PD-1 programs, and povorcitinib asthma Phase 2 data. The FDA action date for the pediatric Opzelura sNDA is September 19, 2025.

  4. Was the Jakafi growth driven by pricing or volume?

    The filing attributes Jakafi's 8% year-over-year net product revenue increase to an 8% increase in paid demand across all indications, and states that Jakafi inventory levels were within normal range at the end of the second quarter of 2025.

04—Continue

← View all 8-K filings